Advertisement

Advertisement

Lung Cancer

Capmatinib Active in Advanced NSCLC With MET Exon 14 Skipping Mutations

As reported inThe New England Journal of Medicine by Jürgen Wolf, MD, of the Center for Integrated Oncology, University Hospital Cologne and University of Cologne, and colleagues, the phase II GEOMETRY mono-1 trial has shown durable responses with the selective MET inhibitor capmatinib in patients...

Lung Cancer

EMPOWER-Lung 1 Trial: Cemiplimab Improves Survival Over Chemotherapy in Advanced NSCLC

The European Society for Medical Oncology (ESMO) Virtual Congress 2020 presented several abstracts with good news for patients with lung cancer. Long-term follow-up of immunotherapies showed excellent survival, a promising new ALK inhibitor improved outcomes compared with the standard of care, the...

Lung Cancer

Lorlatinib Improves Outcomes Over Crizotinib in First-Line Setting of ALK-Positive NSCLC: CROWN Trial

Lorlatinib significantly improved progression-free survival compared with crizotinib in the first-line treatment of patients with advanced ALK-positive non–small cell lung cancer (NSCLC), according to a planned interim analysis of the phase III CROWN trial presented at the European Society for...

Lung Cancer
Kidney Cancer
Leukemia
Solid Tumors
Gastroesophageal Cancer
Gastrointestinal Cancer
Pancreatic Cancer
Prostate Cancer
Genomics/Genetics
Immunotherapy

FDA Pipeline: Priority Reviews in EGFR-Mutant Lung Cancer, Advanced Renal Cell Carcinoma; Fast Track Designations in CLL and Solid Tumors

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for EGFR-mutant lung cancer and advanced renal cell carcinoma; granted Fast Track designation to agents in chronic lymphocytic leukemia (CLL) and locally advanced or metastatic solid tumors; and more....

Lung Cancer
Genomics/Genetics

Do Patients With Early-Stage NSCLC Have a Higher Tumor Mutational Burden Than Those With More Advanced Disease?

The tumors of patients with stage I and II non–small cell lung cancer (NSCLC) demonstrated a generally higher tumor mutational burden and more often displayed the mutational signature associated with tobacco smoking than those of patients with more advanced disease, according to findings presented...

Lung Cancer
Genomics/Genetics

Fragment Analysis as a MET Exon 14 Screening Strategy in NSCLC Tumors

Comparison of two techniques used in screening non–small cell lung cancer (NSCLC) tumor samples demonstrated that fragment analysis could detect large MET exon 14 skipping deletions that were missed by next-generation sequencing, according to findings presented at the Molecular Analysis for...

Lung Cancer
Immunotherapy

Addition of Cetuximab to Afatinib in First-Line Treatment of EGFR-Mutant NSCLC

As reported in the Journal of Clinical Oncology by Sarah B. Goldberg, MD, MPH, and colleagues, final results of the phase II SWOG S1403 trial show no progression-free survival benefit with afatinib plus cetuximab vs afatinib alone in the first-line treatment of EGFR-mutant advanced non–small cell...

Lung Cancer

Association of Adjuvant Chemotherapy With Survival in Early-Stage NSCLC: Do Tumor Size and High-Risk Features Have an Impact?

In a retrospective cohort study reported in JAMA Oncology, Pathak et al found that tumor size alone was not associated with improved survival with adjuvant therapy vs no adjuvant chemotherapy in patients with early-stage, node-negative non–small cell lung cancer (NSCLC). As stated by the...

Lung Cancer
Immunotherapy

Addition of Nivolumab to Neoadjuvant Chemotherapy in Resectable Stage IIIA NSCLC

In the Spanish phase II NADIM trial reported in The Lancet Oncology, Provencio et al found that the addition of nivolumab to neoadjuvant chemotherapy and the use of adjuvant nivolumab were associated with high 24-month rates of progression-free survival in patients with resectable stage IIIA...

Issues in Oncology
Breast Cancer
Colorectal Cancer
Lung Cancer
Genomics/Genetics
Multiple Myeloma
Pancreatic Cancer

Trends to Watch in Early-Onset Cancer Among Young Adults

Although cancer incidence and mortality rates for all cancers combined are considerably lower in younger adults than older adults, a disturbing pattern is beginning to emerge in the development of early-onset cancers, typically diagnosed in older patients, occurring in younger adults. The rising...

Lung Cancer

Pralsetinib for NSCLC With RET Gene Fusions

On September 4, 2020, pralsetinib (Gavreto) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for treatment of adults with metastatic RET fusion–positive non–small cell lung cancer (NSCLC) as detected by an FDA-approved test.1,2 The FDA simultaneously approved the...

Lung Cancer

Expert Point of View: Johan Vansteenkiste, MD

Formal study discussant Johan Vansteenkiste, MD, of the University Hospitals KU Leuven, Belgium, commented on the ADAURA trial findings: “This is an impressive effect on disease-free survival [with osimertinib] and a very early snapshot of overall survival.” Dr. Vansteenkiste continued: “In the CNS ...

Lung Cancer

Impact of Adjuvant Osimertinib on CNS Recurrence of NSCLC: ADAURA Trial

Osimertinib significantly prolonged disease-free survival compared with placebo in patients with completely resected stage II to IIIA non–small cell lung cancer (NSCLC), according to the results of the large randomized phase III ADAURA trial presented at the European Society for Medical Oncology...

Lung Cancer

Expert Point of View: Rafal Dziadziuszko, MD

Commenting on the Lung ART study, Rafal Dziadziuszko, MD, a radiation oncologist from the Medical University of Gdansk, Poland, said: “Congratulations on this study to resolve the longest ongoing debate in thoracic oncology. For more than 20 years, we have been discussing whether to irradiate...

Lung Cancer

Study Questions Role of Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes

The Lung ART trial was designed to demonstrate whether there is any benefit to the routine use of modern mediastinal postoperative radiotherapy in patients with non–small cell lung cancer (NSCLC) stage IIIA N2 (ie, patients with mediastinal nodal involvement) following complete resection and neo...

Lung Cancer
Immunotherapy

First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110

As reported in The New England Journal of Medicine by Roy S. Herbst, MD, PhD, and colleagues, the phase III IMpower110 trial has shown significantly prolonged overall survival with first-line atezolizumab vs platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC)...

Lung Cancer
Genomics/Genetics

Liquid Biopsy May Be a Timely and Effective Testing Method for Patients With NSCLC: Findings From Canada

Next-generation sequencing of cell-free DNA (cfDNA) obtained from blood samples may improve diagnostic testing in patients with advanced non–small cell lung cancer (NSCLC) and may also be faster and less expensive than standard tissue profiling, according to research presented by Natasha B. Leighl, ...

Lung Cancer
Immunotherapy

FDA Approves Nivolumab Plus Ipilimumab for the First-Line Treatment of Unresectable Malignant Pleural Mesothelioma

On October 2, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) as first-line treatment for adult patients with unresectable malignant pleural mesothelioma. CheckMate 743 Efficacy was investigated in CheckMate 743, a randomized,...

Solid Tumors
Lung Cancer
Colorectal Cancer

Activity of the KRAS G12C Inhibitor Sotorasib in KRAS p.G12C–Mutant Advanced Solid Tumors

As reported in The New England Journal of Medicine by David S. Hong, MD, and colleagues, the phase I CodeBreaK100 trial showed activity of the oral KRAS G12C inhibitor sotorasib in heavily pretreated patients with KRAS p.G12C–mutant advanced non–small cell lung cancer (NSCLC), colorectal cancer,...

Lung Cancer
Immunotherapy

Continuous vs Fixed-Duration Immunotherapy in Previously Treated Patients With Advanced NSCLC

In an exploratory analysis of the phase IIIb/IV CheckMate 153 trial published in the Journal of Clinical Oncology, David M. Waterhouse, MD, MPH, and colleagues found that continuing nivolumab beyond 1 year of treatment vs stopping at 1 year of treatment was associated with better outcomes in...

Lung Cancer

Study Examines Combined Impact of Aspirin, Metformin, and Statins on Lung Cancer Risk

Combined use of aspirin, metformin, and statins may be associated with decreased lung cancer incidence and mortality, according to a study published by Kang et al in the Journal of Thoracic Oncology. Study Methods The aim of this study was to investigate the associations of the three agents with...

lung cancer

Cécile Le Pechoux, MD, on NSCLC: Comparing Postoperative Radiotherapy With No Radiotherapy

Cécile Le Pechoux, MD, of the Institut Gustave Roussy, discusses new findings from an international trial on an old controversy: What is the role of postoperative radiotherapy in locally advanced (stage III) non–small cell lung cancer? The researchers enrolled patients with completely resected disease and mediastinal N2 involvement (Abstract LBA3).

lung cancer
immunotherapy

Benjamin Besse, MD, PhD, on NSCLC: Neoadjuvant Atezolizumab for Resectable Disease

Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses results of the phase II PRINCEPS trial, which assessed, for the first time, the effect of just one injection of the immunotherapy atezolizumab before surgery in patients with resectable non–small cell lung cancer (Abstract 1215O).

Lung Cancer

Disease-Free Survival With Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: ADAURA Trial

As reported in The New England Journal of Medicine by Wu et al, the phase III ADAURA trial has shown significantly prolonged disease-free survival with adjuvant osimertinib vs placebo in patients with resected EGFR-mutant non–small cell lung cancer (NSCLC). These findings were also presented during ...

lung cancer

David S. Hong, MD, on NSCLC: Durability of Clinical Benefit and Biomarkers in Patients Treated With Sotorasib

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on sotorasib, a novel, first-in-class, oral KRASG12C inhibitor. The agent demonstrated durable disease control in heavily pretreated patients with non–small cell lung cancer (Abstract 1257O).

Lung Cancer

Study Questions Role of Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes

The Lung ART trial was designed to demonstrate whether there was any benefit to the routine use of modern mediastinal postoperative radiotherapy in patients with non–small cell lung cancer (NSCLC) following complete resection and (neo)adjuvant chemotherapy. No difference in disease-free survival...

Solid Tumors
Lung Cancer

KRAS G12C Inhibitor Shows Activity in Solid Tumors, Lung Cancer

In a phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRAS G12C inhibitor sotorasib (AMG 510) showed manageable toxicities and durable clinical benefits. Results from the trial were published in The New England Journal of Medicine, and data from the ...

lung cancer

Masahiro Tsuboi, MD, on NSCLC: Adjuvant Osimertinib in EGFR-Mutated Disease

Masahiro Tsuboi, MD, of Japan’s National Cancer Center Hospital East, discusses the phase III results from the ADAURA study, which showed a reduced risk of local and distant recurrence in patients with resected EGFR-mutated non–small cell lung cancer, reinforcing adjuvant osimertinib as an effective treatment (Abstract LBA1).

Lung Cancer
Genomics/Genetics

Phase II Trial of Capmatinib for MET Exon 14–Mutated or MET-Amplified Advanced NSCLC

As reported in The New England Journal of Medicine by Wolf et al, the phase II GEOMETRY mono-1 trial has shown durable responses with the selective MET inhibitor capmatinib in patients with advanced non–small cell lung cancer (NSCLC) and MET exon 14–skipping mutations. The trial supported the May...

Lung Cancer
Immunotherapy

First-Line Durvalumab Plus Cisplatin/Pemetrexed in Malignant Pleural Mesothelioma

As reported in The Lancet Oncology by Nowak et al, the Australian phase II DREAM trial showed activity with the triplet of durvalumab plus cisplatin/pemetrexed in previously untreated patients with advanced malignant mesothelioma. Study Details In the multicenter trial, 54 evaluable patients with...

Lung Cancer

Second-Line Carboplatin/Etoposide vs Topotecan in Relapsed Small Cell Lung Cancer

As reported in The Lancet Oncology by Baize et al, a French phase III trial has shown significant improvement in progression-free survival with second-line carboplatin plus etoposide vs topotecan in patients with chemotherapy-sensitive relapsed small cell lung cancer. As noted by the investigators, ...

Lung Cancer

I Say ‘Yes’ to Life

I have been a registered nurse for almost 5 decades and was completely unprepared to hear the words “You have stage IV lung cancer.” I think receiving the diagnosis was especially shocking because the symptoms I began experiencing in the summer of 2015, including some unusual weight gain,...

Lung Cancer

Expert Point of View: Christine M. Lovly, MD, PhD

Invited discussant of the eXalt3 trial, Christine M. Lovly, MD, PhD, Associate Professor of Oncology and Hematology, and Ingram Professor of Cancer Research, and Co-Leader of the Translational Research and Interventional Oncology Program at Vanderbilt University Medical Center and Vanderbilt Ingram ...

Lung Cancer

Ensartinib Doubles Progression-Free Survival in ALK-Positive NSCLC, Phase III Trial Reports

A potent, a next-generation ALK inhibitor has demonstrated promising efficacy in the first-line treatment of patients with advanced ALK-positive non–small cell lung cancer (NSCLC), according to data presented during the 2020 International Association for the Study of Lung Cancer’s World Conference...

Lung Cancer
Immunotherapy

Expert Point of View: Dean A. Fennell, FRCP, PhD

Invited discussant of the CheckMate 743 trial, Dean A. Fennell, FRCP, PhD, Director of the Mesothelioma Research Program and Chair of Thoracic Oncology at The University of Leicester and University Hospitals of Leicester, United Kingdom, noted the combination of nivolumab and ipilimumab has been...

Lung Cancer
Immunotherapy

Nivolumab Plus Ipilimumab: New Standard of Care in First-Line Treatment of Unresectable Malignant Pleural Mesothelioma?

Immunotherapy is taking on yet another highly aggressive cancer and yielding strong results, according to data presented during the 2020 International Association for the Study of Lung Cancer’s World Conference on Lung Cancer Virtual Presidential Symposium.1 A prespecified interim analysis of the...

Lung Cancer

FDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLC

On September 4, the U.S. Food and Drug Administration (FDA) approved pralsetinib (Gavreto) for the treatment of adult patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC), as detected by an FDA-approved test.  The approval is based on data from the phase I/II ARROW...

Multiple Myeloma
Breast Cancer
Lung Cancer
Solid Tumors
Lymphoma
Leukemia
Skin Cancer

FDA Pipeline: Priority Reviews in Multiple Myeloma, Metastatic Breast Cancer, and NSCLC

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to agents for the treatment of refractory multiple myeloma, metastatic breast cancer, and metastatic non–small cell lung cancer (NSCLC); gave Fast Track designation to treatments for NTRK mutation­–positive solid tumors...

Lung Cancer

Research Shows ‘Social Smoking’ Raises Risk of Death From Lung Disease and Lung Cancer

Low-intensity smokers—individuals who smoke fewer than 10 cigarettes per day—are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than nonsmokers, according to research presented by Balte et al at the European Respiratory Society...

Lung Cancer

Selective MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14–Skipping Mutation

As reported in The New England Journal of Medicine by Paul K. Paik, MD, and colleagues, the phase II VISION trial has shown durable responses with the highly selective MET inhibitor tepotinib in patients with non–small cell lung cancer (NSCLC) and MET exon 14–skipping mutation. As noted by the...

Lung Cancer

Osimertinib vs Platinum/Pemetrexed and Overall Survival in Patients With EGFR T790M Advanced NSCLC: AURA3 Trial

In patients with epidermal growth factor receptor (EGFR) T790­M advanced non–small cell lung cancer (NSCLC), no statistically significant benefit in overall survival was observed with osimertinib vs pemetrexed plus carboplatin/cisplatin (platinum/pemetrexed) treatment, which possibly reflects the...

Lung Cancer
Immunotherapy

Is It Time to Add Checkpoint Inhibitors to the Treatment of Locally Advanced Lung Cancer?

After more than 20 years of failed strategies to improve survival rates for locally advanced lung cancers, checkpoint inhibitors have revolutionized therapy, but prognoses still lag behind other tumor types. During the ASCO20 Virtual Education Program, Mark G. Kris, MD, FASCO, a thoracic medical...

Lung Cancer
Immunotherapy

ORIENT-11 Trial Shows Sintilimab Plus Chemotherapy Improves Progression-Free Survival in Advanced NSCLC

The first-line setting for patients with locally advanced or metastatic non-squamous non–small cell lung cancer (NSCLC) now has become more complicated, according to data presented during the 2020 International Association for the Study of Lung Cancer’s World Conference on Lung Cancer Virtual...

lung cancer
covid-19

Marina C. Garassino, MD, on COVID-19 and Thoracic Malignancies: TERAVOLT Registry

Marina C. Garassino, MD, of the Istituto Nazionale dei Tumori di Milano, discusses the global registry she and her colleagues created to track and address the 35% higher mortality risk from COVID-19 among patients with lung cancer who are treated with chemotherapy.

Lung Cancer
Thyroid Cancer

RET Inhibitor Selpercatinib Achieves Durable Responses in Majority of Patients With RET Gene Fusions

For patients with non–small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses in the majority of participants in the phase I/II LIBRETTO-001 trial, according to researchers from The University of...

lung cancer

Leora Horn, MD, on NSCLC: Ensartinib vs Crizotinib in ALK–Positive Disease

Leora Horn, MD, of Vanderbilt University, discusses phase III results from the eXalt3 trial, which suggest that ensartinib, a novel, next-generation ALK inhibitor, is superior to crizotinib in terms of progression-free survival as well as efficacy in central nervous system metastases for patients with ALK-positive non–small cell lung cancer (Abstract 2).

lung cancer

Misako Nagasaka, MD, on NSCLC: Sintilimab, Pemetrexed, and Platinum as First-Line Therapy

Misako Nagasaka, MD, of the Barbara Ann Karmanos Cancer Institute, discusses results of the ORIENT-11 trial, which showed that, although sintilimab plus pemetrexed and platinum significantly improved progression-free survival, the combination only nominally improved overall survival in patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (Abstract 1).

Lung Cancer

Two Organizations Collaborate to Evaluate the Utility of Liquid Biopsy in Treating Lung Cancer

The Cancer Research Institute and The Mark Foundation for Cancer Research have launched an innovative clinical trial that aims to demonstrate the utility of liquid biopsy in assessing responses of patients with lung cancer to immunotherapy (ClinicalTrials.gov identifier NCT04093167). If the trial...

Lung Cancer

Has Racial Disparity in Lung Cancer Incidence Lessened Among Young Adults?

A trend of higher lung cancer incidence rates in young Black people vs young White people in the United States has flipped, with the Black-White gap disappearing in men and reversing in women. The changing trends coincide with steeper declines in smoking among Black Americans, according to a new...

lung cancer
immunotherapy

Paul Baas, MD, PhD, on Mesothelioma: First-Line Nivolumab Plus Ipilimumab vs Chemotherapy

Paul Baas, MD, PhD, of the Netherlands Cancer Institute, discusses results of the CheckMate 743 trial, which suggests nivolumab plus ipilimumab should be considered the new standard of care in first-line treatment of unresectable malignant pleural mesothelioma, regardless of the histology subtype (Abstract 3).

Advertisement

Advertisement

Advertisement